Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Tamsulosin
Drug: Alfuzosin
Drug: Doxazosin

First Posted Date: 2014-10-17

Last Posted Date: 2014-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 97

Registration Number: NCT02266537

Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Flomax®, Norman II facility
Drug: Flomax®, Nishine facility

First Posted Date: 2014-10-17

Last Posted Date: 2014-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02266511

Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBB 515 BS
Other: Standard breakfast (40 g fat)

First Posted Date: 2014-10-17

Last Posted Date: 2014-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02266498

Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2014-10-17

Last Posted Date: 2014-10-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT02266550

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS tablet C
Drug: BIIL 284 BS boli
Other: standard breakfast

First Posted Date: 2014-10-16

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02265640

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: BIIL 284 BS, low dose, adult patients
Drug: BIIL 284 BS, high dose, pediatric patients
Drug: BIIL 284 BS, medium dose, pediatric patients
Drug: BIIL 284 BS, high dose, adult patients
Drug: Placebo
Drug: BIIL 284 BS, low dose, pediatric patients
Drug: BIIL 284 BS, medium dose, adult patients

First Posted Date: 2014-10-16

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT02265679

Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS tablet C
Drug: BIIL 284 BS WIF tablet
Drug: BIIL 284 BS tablet D

First Posted Date: 2014-10-16

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02265653

Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS tablet C
Drug: BIIL 284 BS Tablet FF
Other: standard breakfast

First Posted Date: 2014-10-16

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02265666

Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: BIIL 284 BS

First Posted Date: 2014-10-16

Last Posted Date: 2014-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02265627

The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ethanolic Solution From HFA134a-MDI - low
Drug: Ethanolic Solution From HFA134a-MDI - medium
Drug: Ethanolic Solution From HFA134a-MDI - high
Drug: Ethanolic Solution From Respimat®

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02264145

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy